ClinicalTrials.gg
RecruitingNCT07863128UNCOVERUpdated Oct 7, 2026

Long-Term Recovery and Quality of Life in Sepsis Survivors

An observational study in Sepsis, Long Term Care and Sepsis Scores, sponsored by University of Geneva, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Geneva, Switzerland · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
530
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Sepsis with a site in Switzerland — 9 open to participants now, 9 under way, 1 of them phase 3. Sepsis · Switzerland.

Planned enrollment
7th of 23
530 · median 82
Started
2026
with 2 others
Observational
24 of 49
3 open now
Registered
49th of 49
by date

Among the 49 studies in Sepsis with a site in Switzerland, this one is the 7th largest by planned enrollment of the 23 observational ones that give a count, is one of 3 that started in 2026, is one of 24 observational ones, and was the 49th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

9 of the 49 studies in Sepsis with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Sepsis with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the long-term outcomes and recovery of adult patients admitted to the intensive care unit (ICU) with sepsis.

The main questions it aims to answer are:

  • Which patient-related, infection-related and centre-level factors (for example type of pathogen, time to adequate antibiotic therapy, and local sepsis management practices) are associated with poor quality of life six months after ICU admission for sepsis?
  • How do these factors influence other patient-centred outcomes, such as mortality, psychological and cognitive recovery, functional status and return to work?

This is an international, multicentre, prospective observational cohort study. It will consecutively enrol adult patients (18 years or older) admitted to participating ICUs with sepsis, diagnosed by the treating clinician at ICU admission and, where locally available, meeting Sepsis-3 criteria.

Participants will:

  • have clinical data collected from their medical records at ICU admission, on day 7 and at ICU discharge (infection characteristics, organ support, antibiotic therapy, delirium, rehabilitation and centre organisation);
  • be followed at 28 days (medical record review, or telephone contact if already discharged) and contacted by telephone at 3 months and 6 months after ICU admission for structured assessment of quality of life, psychological and cognitive recovery, functional status, return to work and healthcare utilisation.

The study plans to enrol 600 patients in participating ICUs across several countries, coordinated by Geneva University Hospitals (HUG).

Findings will help identify modifiable factors that may improve long-term recovery and guide future interventions for sepsis survivors.

Read the detailed description

Sepsis is a leading cause of death and long-term disability worldwide. Survivors often experience persistent physical, psychological and cognitive impairments, described as Post-Sepsis Syndrome in addition to Post-Intensive Care Syndrome (PICS). Despite growing recognition of these complications, the factors influencing long-term outcomes - particularly the interaction between individual characteristics, infection-related factors and centre-level practices - remain poorly understood.

UNCOVER is a prospective, international, multicentre observational cohort study designed to investigate these associations in adult ICU patients with sepsis. Geneva University Hospitals (HUG) acts as the promoter. Participating centres enrol patients consecutively; each centre targets 30 consecutive patients during a six-month enrolment period, and enrolment stops once 600 participants have been included. Additional participating ICUs in Europe, the Americas, Asia-Pacific, the Middle East and Africa will be added to this record as local ethics approvals are obtained.

Data are collected from medical records at ICU admission, on day 7 and at ICU discharge, and at follow-up 28 days, 3 months and 6 months after ICU admission. Collected variables include:

  • Centre-level data (collected once per centre): hospital and ICU admission rates, availability of infectious disease consultants and clinical pharmacists, physiotherapist-to-bed ratio, nurse-to-patient and doctor-to-patient ratios, junior/senior physician ratio, proportion of mechanical ventilation beds, existence of a local sepsis bundle, family visiting policy, open/closed ICU, public/private funding, university/non-university status, admissions and patient-days during the study period.
  • Admission data: socio-demographics (age, sex, nationality, ethnicity, employment, financial status), APACHE II, SOFA, comorbidities (Charlson Comorbidity Index and individual comorbidities), Clinical Frailty Scale, CAM-ICU, Glasgow Coma Scale, baseline psychiatric comorbidity, code status (full code, DNR, DNI), intubation, vasopressors.
  • Day 7 data: SOFA, GCS, delirium (CAM-ICU), cultures obtained and positive cultures with pathogen, resistance and antibiogram details, antibiotic adaptation, code status, intubation, vasopressors.
  • ICU discharge data: source of infection, source control measures, time to adequate antibiotic therapy, type and duration of antibiotic therapy, new sepsis episodes during the ICU stay, imaging, mechanical ventilation and its duration, tracheostomy, new organ failures, dialysis, ECMO, delirium duration and treatment, caloric intake and deficit, thiamine and steroid administration, Barthel Index at ICU discharge.
  • Environmental data: ICU diary, number of physiotherapy sessions per ICU length of stay, family presence at the bedside.

Because patients with sepsis are in an emergency situation and frequently lack decision-making capacity (altered consciousness, sedation, intubation), immediate inclusion with deferred consent is used, in accordance with articles 30 and 31 of the Swiss Human Research Act: advance directives are consulted, an independent physician not involved in the research safeguards the patient's interests, proxy consent is obtained from the legal representative or next of kin as soon as possible, and consent is requested from the patient post hoc as soon as capacity is recovered.

The primary outcome is health-related quality of life measured with the EQ-5D-5L at 6 months; poor quality of life is defined a priori as an EQ-5D-5L index value below 0.6. Secondary outcomes include 6-month mortality, broader quality of life (SF-12), cognitive function (T-MoCA), post-traumatic stress symptoms (IES-R), functional status (Barthel Index, extended Barthel, IADL), frailty (Clinical Frailty Scale), return to work and socio-economic recovery, rehospitalisation and healthcare utilisation, and patient-reported decision regret and preferences regarding future ICU admission.

Pre-specified secondary analyses will examine the association between long-term patient-centred outcomes and: sepsis-related delirium during the ICU stay; duration of antibiotic therapy (7 days or less versus more than 7 days); time to adequate antibiotic therapy; hospital-acquired versus community-acquired sepsis; immunosuppression; hyperoxia exposure during the ICU stay; and clinical parameters before initiation of renal replacement therapy as predictors of renal recovery and associated long-term quality of life.

The primary analysis uses a hierarchical logistic regression model with centre as a random intercept, with predictors at centre level (country), patient level (Clinical Frailty Scale, Charlson Comorbidity Index, SOFA) and infection level (time to adequate antibiotic therapy, source control achieved). Six-month mortality is analysed with a shared-frailty Cox model with centre as the frailty term. Analyses are performed in R (version 4.3 or higher) and STATA 16.1.

No experimental intervention is administered; all treatments follow local standard of care and remain the responsibility of the attending medical team. Data are coded at source and entered into a secure REDCap registry hosted by the Swiss Society of Intensive Care Medicine (SGI/SSMI).

The study is supported by a EUR 20,000 grant from the European Society of Intensive Care Medicine (ESICM), which has no role in the design, conduct, data collection, analysis, interpretation or decision to publish.

03

Conditions studied

  • Sepsis
  • Long Term Care
  • Sepsis Scores
  • Long Term Follow-Up
  • Long Term Outcomes
  • PICS

Browse trials for

Keywords

  • sepsis
  • long term outcomes
  • follow-up
  • sepsis sequelae
  • sepsis outcomes
  • quality of life
  • pics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (18 years or older) consecutively admitted to participating ICUs with community- or hospital-acquired sepsis diagnosed by the treating clinician at ICU admission and, where locally available, meeting Sepsis-3 criteria. Participating ICUs are academic and non-academic centres in several countries. Participants represent a broad spectrum of disease severity, comorbidity and infection source. Sepsis acquired in the ICU and patients admitted for palliative care are not included. No experimental intervention is administered; all treatments follow local standard of care. Because sepsis is an emergency condition and patients frequently lack decision-making capacity at the time of ICU admission, patients are included immediately and consent is obtained from a legal representative or next of kin as soon as possible and from the patient post hoc once capacity is recovered, in accordance with articles 30 and 31 of the Swiss Human Research Act.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • Sepsis (community- or hospital-acquired) diagnosed on ICU admission, defined as either: (a) a diagnosis of sepsis made by the treating clinician at ICU admission AND fulfilment of Sepsis-3 criteria; or (b) a diagnosis of sepsis made by the treating clinician at ICU admission alone, where Sepsis-3 criteria are not routinely available according to local protocol

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate, by the patient or the legal representative
  • Inability to ensure follow-up (e.g. overseas residence, no fixed home address)
  • Sepsis acquired in the ICU
  • Patient admitted for palliative care
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
530 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Sepsis Survivors Cohort

    This cohort includes adult patients (≥18 years) admitted to participating intensive care units (ICUs) with a diagnosis of sepsis according to SEPSIS-3 criteria. Participants will be followed prospectively at 28 days, 3 months, and 6 months after ICU admission to assess patient-centered outcomes including quality of life, functional recovery, cognitive status, and mental health. No experimental interventions will be administered; all treatments follow standard clinical practice. Data on infection characteristics, antibiotic timing, and ICU management will be recorded for association analyses.

    Other: Care for Sepsis

Interventions

  • OtherCare for Sepsis

    Participants will receive standard clinical care for sepsis according to local hospital protocols. This study is purely observational: no experimental drugs, procedures, or behavioral interventions are introduced. Data will be collected prospectively on infection characteristics, timing of adequate antibiotic therapy, organ support, and rehabilitation practices during the ICU stay. Follow-up at 28 days, 3 months, and 6 months will assess patient-centered outcomes such as quality of life (EQ-5D-5L), cognitive and mental health status, and return to work. All treatments and decisions remain under the responsibility of the attending medical team.

06

What researchers measure

Primary outcomes

  1. Health-related Quality of Life

    Health-related quality of life measured with the EQ-5D-5L. The EQ-5D-5L index value ranges approximately from below 0 to 1, with higher values indicating better health-related quality of life. Poor quality of life is defined a priori as an index value below 0.6.

    Time frame: 6 months after ICU admission

Secondary outcomes

  1. Health-related Quality of Life

    Health-related quality of life measured with the EQ-5D-5L. The EQ-5D-5L index value ranges approximately from below 0 to 1, with higher values indicating better health-related quality of life. Poor quality of life is defined a priori as an index value below 0.6.

    Time frame: 7 days after ICU admission

  2. Health-related Quality of Life

    Health-related quality of life measured with the EQ-5D-5L. The EQ-5D-5L index value ranges approximately from below 0 to 1, with higher values indicating better health-related quality of life. Poor quality of life is defined a priori as an index value below 0.6.

    Time frame: 28 days after ICU admission

  3. Health-related Quality of Life

    Health-related quality of life measured with the EQ-5D-5L. The EQ-5D-5L index value ranges approximately from below 0 to 1, with higher values indicating better health-related quality of life. Poor quality of life is defined a priori as an index value below 0.6.

    Time frame: 3 months after ICU admission

  4. 6-Month Mortality

    All-cause mortality within 6 months of ICU admission, ascertained from medical records or during structured follow-up contact. Includes deaths during the index hospitalisation and after discharge. Cause of death is recorded, including death following withdrawal or withholding of life-sustaining treatment.

    Time frame: 6 months after ICU admission

  5. Cognitive Function

    Cognitive function assessed by the Telephone Montreal Cognitive Assessment (T-MoCA). Lower scores indicate greater cognitive impairment. Cognitive impairment is defined a priori as a T-MoCA score below 12.

    Time frame: 6 months after ICU admission

  6. Cognitive Function

    Cognitive function assessed by the Telephone Montreal Cognitive Assessment (T-MoCA). Lower scores indicate greater cognitive impairment. Cognitive impairment is defined a priori as a T-MoCA score below 12.

    Time frame: 3 months after ICU admission

  7. Psychological Distress and Post-Traumatic Stress Symptoms

    Post-traumatic stress symptoms assessed with the Impact of Event Scale-Revised (IES-R, range 0 to 88). Analysed as a continuous score; clinically significant post-traumatic stress is defined a priori as a score above 33.

    Time frame: 6 months after ICU admission

  8. Psychological Distress and Post-Traumatic Stress Symptoms

    Post-traumatic stress symptoms assessed with the Impact of Event Scale-Revised (IES-R, range 0 to 88). Analysed as a continuous score; clinically significant post-traumatic stress is defined a priori as a score above 33.

    Time frame: 3 months after ICU admission

  9. Functional Status

    Barthel Index recorded at ICU discharge and at day 28, from medical record review or telephone contact if the patient has already been discharged. Lower scores indicate greater functional dependency.

    Time frame: 3 months after ICU admission

  10. Functional Status

    Barthel Index recorded at ICU discharge and at day 28, from medical record review or telephone contact if the patient has already been discharged. Lower scores indicate greater functional dependency.

    Time frame: 6 months after ICU admission

  11. Return to Work and Socioeconomic Recovery

    Self-reported return to paid employment, whether family caregivers resumed work, whether the participant receives nursing support at home, and financial status (no difficulty, new difficulty, or same as before sepsis), recorded during structured telephone follow-up.

    Time frame: 6 months after ICU admission

  12. Return to Work and Socioeconomic Recovery

    Self-reported return to paid employment, whether family caregivers resumed work, whether the participant receives nursing support at home, and financial status (no difficulty, new difficulty, or same as before sepsis), recorded during structured telephone follow-up.

    Time frame: 3 months after ICU admission

  13. Rehospitalization and Healthcare Utilization

    Cumulative number and causes of rehospitalisations and outpatient consultations, collected through medical record review and participant self-report during the follow-up interview.

    Time frame: 6 months after ICU admission

  14. Decision regret regarding the ICU stay (Decision Regret Scale)

    Regret regarding the ICU stay assessed with the five-item Decision Regret Scale, administered during structured telephone follow-up. Item responses are summed and linearly transformed to a total score ranging from 0 (no regret) to 100 (maximum regret); higher scores indicate greater regret. The continuous score is the registered outcome measure. For dichotomised analyses, moderate-to-strong regret is defined a priori as a score above 25, with a score of 0 indicating no regret and 1 to 25 indicating mild regret. Where a participating centre administers a validated language version with a different reported threshold, that threshold will be applied in pre-specified sensitivity analyses.

    Time frame: 6 months after ICU admission

  15. Freedom from renal replacement therapy

    Percentage of participants who are alive and free from renal replacement therapy 6 months after ICU admission, among those who received renal replacement therapy for sepsis-associated acute kidney injury during the ICU stay. Freedom from renal replacement therapy is defined as no renal replacement therapy of any modality during the 30 days preceding the 6-month assessment, ascertained from medical record review and structured telephone follow-up. Participants who died before the 6-month assessment are counted as not having recovered renal function.

    Time frame: 6 months after ICU admission

  16. Physical health-related quality of life (Short Form-12 Physical Component Summary)

    Physical Component Summary (PCS) score of the Short Form-12 Health Survey (SF-12), administered during structured telephone follow-up. The PCS is a norm-based score calibrated to a general-population mean of 50 and standard deviation of 10, ranging from 0 (worst physical health) to 100 (best physical health); higher scores indicate better physical health. The continuous score is the registered outcome measure. For dichotomised analyses, impaired physical health is defined a priori as a PCS score more than one standard deviation below the general-population norm (score below 40); where a country-specific general-population norm is available for a participating centre, that norm will be used in pre-specified sensitivity analyses.

    Time frame: 3 months after ICU admission

  17. Delirium during the ICU stay

    Presence of delirium assessed with the CAM-ICU during the ICU stay, with duration of delirium and treatments administered.

    Time frame: 6 months after ICU admission

  18. Mental health-related quality of life (Short Form-12 Mental Component Summary)

    Mental Component Summary (MCS) score of the Short Form-12 Health Survey (SF-12), administered during structured telephone follow-up. The MCS is a norm-based score calibrated to a general-population mean of 50 and standard deviation of 10, ranging from 0 (worst mental health) to 100 (best mental health); higher scores indicate better mental health. The continuous score is the registered outcome measure. For dichotomised analyses, impaired mental health is defined a priori as an MCS score more than one standard deviation below the general-population norm (score below 40); where a country-specific general-population norm is available for a participating centre, that norm will be used in pre-specified sensitivity analyses.

    Time frame: 3 months after ICU admission

  19. Mental health-related quality of life (Short Form-12 Mental Component Summary)

    Mental Component Summary (MCS) score of the Short Form-12 Health Survey (SF-12), administered during structured telephone follow-up. The MCS is a norm-based score calibrated to a general-population mean of 50 and standard deviation of 10, ranging from 0 (worst mental health) to 100 (best mental health); higher scores indicate better mental health. The continuous score is the registered outcome measure. For dichotomised analyses, impaired mental health is defined a priori as an MCS score more than one standard deviation below the general-population norm (score below 40); where a country-specific general-population norm is available for a participating centre, that norm will be used in pre-specified sensitivity analyses.

    Time frame: 6 months after ICU admission

  20. Physical health-related quality of life (Short Form-12 Physical Component Summary)

    Physical Component Summary (PCS) score of the Short Form-12 Health Survey (SF-12), administered during structured telephone follow-up. The PCS is a norm-based score calibrated to a general-population mean of 50 and standard deviation of 10, ranging from 0 (worst physical health) to 100 (best physical health); higher scores indicate better physical health. The continuous score is the registered outcome measure. For dichotomised analyses, impaired physical health is defined a priori as a PCS score more than one standard deviation below the general-population norm (score below 40); where a country-specific general-population norm is available for a participating centre, that norm will be used in pre-specified sensitivity analyses.

    Time frame: 6 months after ICU admission

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 12 months is below that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 7, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863128
Lead sponsor
University of Geneva, Switzerland
Collaborators
University of Zurich, University Health Network, Toronto, University of Sydney, European Society of Intensive Care Medicine, Università degli Studi di Trento, University Hospital, Geneva
Responsible party
Hannah Wozniak (Principal Investigator, Division of Intensive Care, University of Geneva, Switzerland) — Principal investigator
First posted
Oct 7, 2026
Start date
Sep 1, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Hannah Wozniak, MD
Contact
hannah.wozniak@hug.ch
+41 (7)95530291
Niccolo' Buetti, MD
study chair · Geneva University Hospitals (HUG)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion